Clinical Trial Update: Sorafenib in Resected Non-small Cell Lung Carcinoma [Phase 2]

View source ↗

Summary

This document reports that the Phase 2 trial of sorafenib in patients with resected non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Johannes Gutenberg University Mainz | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: TERMINATED